Compare Stocks: SKYE, ATRA, GANX, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.54 -2.6%	$9.63	$3.92 ▼ $19.15	$79.02M	0.12	76,490 shs	32,524 shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$75.07M	0.19	588,113 shs	293,835 shs
IBIO iBio	$1.40 -4.1%	$1.59	$0.56 ▼ $3.82	$72.53M	1.3	829,714 shs	304,202 shs
SKYE Skye Bioscience	$0.56 -2.3%	$0.69	$0.55 ▼ $4.99	$20.21M	2.97	128,963 shs	106,581 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-2.62%	+5.96%	-21.51%	-14.00%	-23.89%
GANX Gain Therapeutics	+2.27%	+6.51%	-0.55%	-3.74%	+7.78%
IBIO iBio	-4.11%	+2.94%	-13.58%	-14.63%	+139,999,900.00%
SKYE Skye Bioscience	-2.31%	-8.67%	-20.13%	-37.47%	-85.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.54 -2.6%	$9.63	$3.92 ▼ $19.15	$79.02M	0.12	76,490 shs	32,524 shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$75.07M	0.19	588,113 shs	293,835 shs
IBIO iBio	$1.40 -4.1%	$1.59	$0.56 ▼ $3.82	$72.53M	1.3	829,714 shs	304,202 shs
SKYE Skye Bioscience	$0.56 -2.3%	$0.69	$0.55 ▼ $4.99	$20.21M	2.97	128,963 shs	106,581 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	-2.62%	+5.96%	-21.51%	-14.00%	-23.89%
GANX Gain Therapeutics	+2.27%	+6.51%	-0.55%	-3.74%	+7.78%
IBIO iBio	-4.11%	+2.94%	-13.58%	-14.63%	+139,999,900.00%
SKYE Skye Bioscience	-2.31%	-8.67%	-20.13%	-37.47%	-85.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.00	Hold	$9.50	11.24% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	316.67% Upside
IBIO iBio	3.13	Buy	$5.00	257.14% Upside
SKYE Skye Bioscience	2.50	Moderate Buy	$8.50	1,413.26% Upside

Current Analyst Ratings Breakdown

Latest SKYE, ATRA, GANX, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
7/1/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
6/30/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/24/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
6/9/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$120.77M	0.64	$4.74 per share	1.80	($5.34) per share	-1.60
GANX Gain Therapeutics	$50K	1,535.40	N/A	N/A	$0.48 per share	3.75
IBIO iBio	$400K	173.88	N/A	N/A	$0.90 per share	1.56
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$0.62 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$0.67	N/A	6.10	N/A	-40.91%	-79.12%	-35.29%	8/10/2026 (Estimated)
GANX Gain Therapeutics	-$20.16M	-$0.58	N/A	N/A	N/A	N/A	-201.44%	-136.24%	8/11/2026 (Estimated)
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)
SKYE Skye Bioscience	-$55.92M	-$1.44	N/A	N/A	N/A	N/A	-217.27%	-162.39%	N/A

Latest SKYE, ATRA, GANX, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.14	N/A	N/A	N/A	$0.03 million	N/A
8/10/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	N/A	N/A	N/A	$0.55 million	N/A
5/12/2026	Q1 2026	ATRA Atara Biotherapeutics	-$0.3295	-$0.29	+$0.0395	-$0.29	$2.90 million	$0.52 million
5/12/2026	Q3 2026	IBIO iBio	-$0.06	-$0.07	-$0.01	-$0.06	$0.02 million	N/A
5/11/2026	Q1 2026	GANX Gain Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$0.03 million	N/A
5/11/2026	Q1 2026	SKYE Skye Bioscience	-$0.29	-$0.32	-$0.03	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	2.16	2.16
GANX Gain Therapeutics	0.02	4.69	4.69
IBIO iBio	N/A	11.88	11.88
SKYE Skye Bioscience	N/A	1.78	1.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
GANX Gain Therapeutics	11.97%
IBIO iBio	7.90%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
GANX Gain Therapeutics	4.15%
IBIO iBio	2.75%
SKYE Skye Bioscience	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	9.01 million	5.30 million	No Data
GANX Gain Therapeutics	20	42.65 million	40.88 million	Optionable
IBIO iBio	100	49.68 million	48.31 million	N/A
SKYE Skye Bioscience	11	35.14 million	32.97 million	Optionable

SKYE, ATRA, GANX, and IBIO Headlines

Recent News About These Companies

Skye Bioscience (NASDAQ:SKYE) Shares Up 2.8% - What's Next?

August 4 at 2:02 AM | americanbankingnews.com

Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE

July 12, 2026 | natlawreview.comN

Cadrenal Therapeutics Names Sharp Interim CFO

June 29, 2026 | marketwatch.com

Skye Bioscience Expands Authorized Shares After Shareholder Approval

May 29, 2026 | tipranks.com

Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1

May 20, 2026 | globenewswire.com

Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87

May 14, 2026 | msn.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)

May 14, 2026 | theglobeandmail.com

Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 14, 2026 | finanznachrichten.de

Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE

May 13, 2026 | natlawreview.comN

Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026

May 12, 2026 | quiverquant.comQ

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 12, 2026 | globenewswire.com

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

May 11, 2026 | globenewswire.com

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

April 22, 2026 | globenewswire.com

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

April 7, 2026 | globenewswire.com

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

April 2, 2026 | globenewswire.com

Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...

March 11, 2026 | finance.yahoo.com

Skye Bioscience, Inc.: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 11, 2026 | finanznachrichten.de

Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy

March 11, 2026 | msn.com

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

March 10, 2026 | seekingalpha.com

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, ATRA, GANX, and IBIO Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$8.54 -0.23 (-2.62%)

As of 08/5/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Gain Therapeutics NASDAQ:GANX

$1.80 +0.04 (+2.27%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.76 -0.04 (-2.22%)

As of 08/5/2026 07:54 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

iBio NASDAQ:IBIO

$1.40 -0.06 (-4.11%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.39 -0.01 (-0.71%)

As of 06:05 AM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Skye Bioscience NASDAQ:SKYE

$0.56 -0.01 (-2.31%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$0.56 +0.00 (+0.59%)

As of 06:25 AM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SKYE, ATRA, GANX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SKYE, ATRA, GANX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SKYE, ATRA, GANX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, ATRA, GANX, and IBIO Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SKYE, ATRA, GANX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SKYE, ATRA, GANX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SKYE, ATRA, GANX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, ATRA, GANX, and IBIO Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

Skye Bioscience NASDAQ:SKYE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools